Stocks of Dynavax Technologies Corporation (NASDAQ:DVAX) traded higher last session on Wall Street, down -1.29% to $13.81.
According to the data, Dynavax Technologies Corporation (NASDAQ:DVAX) has 5 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $27.00 and a low of $21.00, we find $24.50. Given the previous closing price of $13.99, this indicates a potential upside of 75.13 percent. DVAX stock price is now 8.41% away from the 50-day moving average and 20.18% away from the 200-day moving average. The market capitalization of the company currently stands at $1.76B.
A total of 0 analysts have issued a hold rating and 5 have given it a buy rating. Brokers who have rated the stock have averaged $24.25 as their price target over the next twelve months.
With the price target of $22, JMP Securities recently initiated with Mkt Outperform rating for Dynavax Technologies Corporation (NASDAQ: DVAX).
In other news, Hack Andrew A. F., Director sold 500,000 shares of the company’s stock on Jun 14. The stock was sold for $6,340,000 at an average price of $12.68. Upon completion of the transaction, the Director now directly owns 2,415,000 shares in the company, valued at $33.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 18, Director Hack Andrew A. F. sold 1,000,000 shares of the business’s stock. A total of $10,550,000 was realized by selling the stock at an average price of $10.55. This leaves the insider owning 2,915,000 shares of the company worth $40.26 million. Insiders disposed of 6,257,921 shares of company stock worth roughly $86.42 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DVAX stock. A new stake in Dynavax Technologies Corporation shares was purchased by MIZUHO MARKETS CAYMAN LP during the first quarter worth $10,453,000. PEREGRINE CAPITAL MANAGEMENT LLC invested $7,746,000 in shares of DVAX during the first quarter. In the first quarter, STONEPINE CAPITAL MANAGEMENT, LLC acquired a new stake in Dynavax Technologies Corporation valued at approximately $5,752,000. HRT FINANCIAL LP acquired a new stake in DVAX for approximately $2,836,000. EA SERIES TRUST purchased a new stake in DVAX valued at around $2,541,000 in the second quarter. In total, there are 303 active investors with 92.80% ownership of the company’s stock.
During the past 12 months, Dynavax Technologies Corporation has had a low of $9.42 and a high of $17.48. As of last week, the company has a debt-to-equity ratio of 0.39, a current ratio of 9.10, and a quick ratio of 8.40. The fifty day moving average price for DVAX is $12.80 and a two-hundred day moving average price translates $11.51 for the stock.
The latest earnings results from Dynavax Technologies Corporation (NASDAQ: DVAX) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.19, missing analysts’ expectations of -$0.13 by -0.06. This compares to $0.22 EPS in the same period last year. The net profit margin was 35.90% and return on equity was 45.60% for DVAX. The company reported revenue of $46.92 million for the quarter, compared to $113.99 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -58.83 percent. For the current quarter, analysts expect DVAX to generate $48.38M in revenue.
Dynavax Technologies Corporation(DVAX) Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
